[HTML][HTML] Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss, KK Burkhart… - BMC …, 2020 - Springer
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
Predicting potential adverse events using safety data from marketed drugs.
C Daluwatte, P Schotland, DG Strauss… - BMC …, 2020 - europepmc.org
BACKGROUND: While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
[HTML][HTML] Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss… - BMC …, 2020 - ncbi.nlm.nih.gov
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss… - BMC …, 2020 - search.proquest.com
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
[HTML][HTML] Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland… - BMC …, 2020 - bmcbioinformatics.biomedcentral …
While clinical trials are considered the gold standard for detecting adverse events, often
these trials are not sufficiently powered to detect difficult to observe adverse events. We …
these trials are not sufficiently powered to detect difficult to observe adverse events. We …
Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss… - BMC …, 2020 - pubmed.ncbi.nlm.nih.gov
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
Predicting potential adverse events using safety data from marketed drugs.
C Daluwatte, P Schotland, DG Strauss… - BMC …, 2020 - go.gale.com
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
[PDF][PDF] Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss, KK Burkhart… - 2020 - scholar.archive.org
Background: While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss, KK Burkhart… - BMC …, 2020 - osti.gov
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
Predicting potential adverse events using safety data from marketed drugs
C Daluwatte, P Schotland, DG Strauss, KK Burkhart… - 2020 - agris.fao.org
Background While clinical trials are considered the gold standard for detecting adverse
events, often these trials are not sufficiently powered to detect difficult to observe adverse …
events, often these trials are not sufficiently powered to detect difficult to observe adverse …